

Curriculum Vitae Dr Mario Polywka

Academic degree: DPhil in mechanistic organometallic chemistry, University of Oxford

Occupation: Consultant

Place of residence: Abingdon, UK

Personal data

Year of birth: 1963

Nationality: British

Member of the Supervisory Board of Evotec SE

n/a

Education

1988 – 1989 University of Oxford

PostDoc

1985 – 1988 University of Oxford

Conferral of a doctorate (DPhil in mechanistic organometallic chemistry)

1981 – 1985 University of Oxford

Bachelor of Arts

Professional career

Since Jan 2019 Consultant

2007 – 2018 Evotec AG

Member of Management Board and Chief Operating Officer

2004 – 2006 Evotec AG

Executive Vice President

2002 – 2004 Consultant

1991 – 2002 Evotec OAI AG

Various positions, most recently Chief Operating Officer

Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises

Forge Therapeutics, Inc. (Member of the Board of Directors)

Exscientia Ltd. (Member of the Board of Directors)

Other significant activities besides the Supervisory Board mandate

n/a

Relevant knowledge, skills and experience

Dr Mario Polywka (born in 1963, British citizen) retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he has served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007. In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor's degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994. Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd.

Due to his expert knowledge in drug discovery and development, his long-term commercial, operational, and strategic record of accomplishment and because of his comprehensive knowledge of the Company, Dr Polywka ideally complements the future Supervisory Board of Evotec SE.

Personal or business relationships in accordance with section 5.4.1 paragraphs 6 to 8 of the German Corporate Governance Code

In the opinion of the Supervisory Board, Dr Mario Polywka and Evotec SE, its affiliates, the bodies of Evotec SE or a significant shareholder in Evotec SE, have no personal or business relationships that an objective judging shareholder would consider authoritative for their voting decision. Shareholders who directly or indirectly hold more than 10% of the Company's voting shares are considered as significant shareholders.